Status:
COMPLETED
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Epidermolysis Bullosa
Eligibility:
All Genders
6+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epid...
Detailed Description
Potential subjects came to the for a screening visit. Eligible subjects had baseline assessments performed and were provided study medication, allantoin 3% cream. Subjects were instructed to apply the...
Eligibility Criteria
Inclusion
- history of epidermolysis bullosa
Exclusion
- use of any skin product containing allantoin for 30 days prior to enrollment
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00825565
Start Date
February 1 2009
End Date
November 1 2010
Last Update
February 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert and Ann Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611